|
1
|
Tanaka H, Shinto O, Yashiro M, et al:
Transforming growth factor beta signaling inhibitor, SB-431542,
induces maturation of dendritic cells and enhances anti-tumor
activity. Oncol Rep. 24:1637–1643. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kushwah R and Hu J: Complexity of
dendritic cell subsets and their function in the host immune
system. Immunology. 133:409–419. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Phuc PV, Lam DH, Ngoc VB, Thu DT, Nguyet
NT and Ngoc PK: Production of functional dendritic cells from
menstrual blood-a new dendritic cell source for immune therapy. In
Vitro Cell Dev Biol Anim. 47:368–375. 2011.PubMed/NCBI
|
|
4
|
Guermonprez P, Valladeau J, Zitvogel L,
Thery C and Amigorena S: Antigen presentation and T cell
stimulation by dendritic cells. Annu Rev Immunol. 20:621–667. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pawlowska AB, Hashino S, McKenna H, Weigel
BJ, Taylor PA and Blazar BR: In vitro tumor-pulsed or in vivo Flt3
ligand-generated dendritic cells provide protection against acute
myelogenous leukemia in non-transplanted or syngeneic bone
marrow-transplanted mice. Blood. 97:1474–1482. 2001. View Article : Google Scholar
|
|
6
|
Onaitis M, Kalady MF, Pruitt S and Tyler
DS: Dendritic cell gene therapy. Surg Oncol Clin N Am. 11:645–660.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trivedi D, Williams RY, O'Reilly RJ and
Koehne G: Generation of CMV-specific T lymphocytes using
protein-spanning pools of pp65-derived overlapping
pentadecapeptides for adoptive immunotherapy. Blood. 105:2793–2801.
2005. View Article : Google Scholar
|
|
8
|
Bachleitner-Hofmann T, Friedl J, Hassler
M, et al: Pilot trial of autologous dendritic cells loaded with
tumor lysate(s) from allogeneic tumor cell lines in patients with
metastatic medullary thyroid carcinoma. Oncol Rep. 21:1585–1592.
2009. View Article : Google Scholar
|
|
9
|
Xiao ZY, Tang H, Xu ZM, et al: An
experimental study of dendritic cells transfected with cancer
stem-like cells RNA against 9L brain tumors. Cancer Biol Ther.
11:974–980. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Palucka AK, Ueno H, Connolly J, et al:
Dendritic cells loaded with killed allogeneic melanoma cells can
induce objective clinical responses and MART-1 specific
CD8+ T-cell immunity. J Immunother. 29:545–557. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun L, Liu J, Cao X, et al: Enhancement of
antigen presenting function of dendritic cells by IL-2 gene
modification and its mechanism. Zhonghua Xue Ye Xue Za Zhi.
23:247–250. 2002.(In Chinese).
|
|
12
|
Harrington L, Zhou W, McPhail T, et al:
Human telomerase contains evolutionarily conserved catalytic and
structural subunits. Genes Dev. 11:3109–3115. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Collins K and Mitchell JR: Telomerase in
the human organism. Oncogene. 21:564–579. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shay JW, Zou Y, Hiyama E and Wright WE:
Telomerase and cancer. Hum Mol Genet. 10:677–685. 2001. View Article : Google Scholar
|
|
15
|
Zhang P, Chen Y, Jiang X, Tu Z and Zou L:
Tumor-targeted efficiency of shRNA vector harboring chimera
hTERT/U6 promoter. Oncol Rep. 23:1309–1316. 2010.PubMed/NCBI
|
|
16
|
Li H, Wang J, Zhou T, Zhang Y and Zhang Z:
An investigation of the effects of nanosize delivery system for
antisense oligonucleotide on esophageal squamous cancer cells.
Cancer Biol Ther. 7:1852–1859. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Keith WN, Bilsland A, Evans TR and
Glasspool RM: Telomerase-directed molecular therapeutics. Expert
Rev Mol Med. 4:1–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vonderheide RH, Hahn WC, Schultze JL and
Nadler LM: The telomerase catalytic subunit is a widely expressed
tumor-associated antigen recognized by cytotoxic T lymphocytes.
Immunity. 10:673–679. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang JJ, Lin MC, Bai YX, et al: Ectopic
expression of a COOH-terminal fragment of the human telomerase
reverse transcriptase leads to telomere dysfunction and reduction
of growth and tumorigenicity in HeLa cells. Cancer Res.
62:3226–3232. 2002.
|
|
20
|
Ng SS, Gao Y, Chau DH, et al: A novel
glioblastoma cancer gene therapy using AAV-mediated long-term
expression of human TERT C-terminal polypeptide. Cancer Gene Ther.
14:561–572. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huo L, Yao H, Wang X, Wong GW, Kung HF and
Lin MC: Inhibition of melanoma growth by subcutaneous
administration of hTERTC27 viral cocktail in C57BL/6 mice. PLoS
One. 5:e127052010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang JY, Cao DY, Liu WC, Zhang HM, Teng ZH
and Ren J: Dendritic cell generated from CD34+
hematopoietic progenitors can be transfected with adenovirus
containing gene of HBsAg and induce antigen-specific cytotoxic T
cell responses. Cell Immunol. 240:14–21. 2006.PubMed/NCBI
|
|
23
|
Chen T, Tang XD, Wan Y, et al:
HLA-A2-restricted cytotoxic T lymphocyte epitopes from human
heparanase as novel targets for broad-spectrum tumor immunotherapy.
Neoplasia. 10:977–986. 2008.PubMed/NCBI
|
|
24
|
Inaba K, Inaba M, Romani N, et al:
Generation of large numbers of dendritic cells from mouse bone
marrow cultures supplemented with granulocyte/macrophage
colony-stimulating factor. J Exp Med. 176:1693–1702. 1992.
View Article : Google Scholar
|
|
25
|
Berzofsky JA, Terabe M, Oh S, et al:
Progress on new vaccine strategies for the immunotherapy and
prevention of cancer. J Clin Invest. 113:1515–1525. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vonderheide RH, Domchek SM, Schultze JL,
et al: Vaccination of cancer patients against telomerase induces
functional antitumor CD8+ T lymphocytes. Clin Cancer
Res. 10:828–839. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nestle FO, Alijagic S, Gilliet M, et al:
Vaccination of melanoma patients with peptide- or tumor
lysate-pulsed dendritic cells. Nat Med. 4:328–332. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huo LF, Tang JW, Huang JJ, et al: Cancer
immunotherapy targeting the telomerase reverse transcriptase. Cell
Mol Immunol. 3:1–11. 2006.PubMed/NCBI
|
|
29
|
Vonderheide RH, Anderson KS, Hahn WC,
Butler MO, Schultze JL and Nadler LM: Characterization of
HLA-A3-restricted cytotoxic T lymphocytes reactive against the
widely expressed tumor antigen telomerase. Clin Cancer Res.
7:3343–3348. 2001.PubMed/NCBI
|
|
30
|
Scardino A, Gross DA, Alves P, et al:
HER-2/neu and hTERT cryptic epitopes as novel targets for broad
spectrum tumor immunotherapy. J Immunol. 168:5900–5906. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Minev B, Hipp J, Firat H, Schmidt JD,
Langlade-Demoyen P and Zanetti M: Cytotoxic T cell immunity against
telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA.
97:4796–4801. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rabinovich PM, Komarovskaya ME, Wrzesinski
SH, et al: Chimeric receptor mRNA transfection as a tool to
generate antineoplastic lymphocytes. Hum Gene Ther. 20:51–61. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iuchi T, Teitz-Tennenbaum S, Huang J, et
al: Interleukin-21 augments the efficacy of T-cell therapy by
eliciting concurrent cellular and humoral responses. Cancer Res.
68:4431–4441. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dredge K, Marriott JB, Todryk SM, et al:
Protective antitumor immunity induced by a costimulatory
thalidomide analog in conjunction with whole tumor cell vaccination
is mediated by increased Th1-type immunity. J Immunol.
168:4914–4919. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pletneva M, Fan H, Park JJ, et al:
IFN-producing killer dendritic cells are antigen-presenting cells
endowed with T-cell cross-priming capacity. Cancer Res.
69:6607–6614. 2009. View Article : Google Scholar : PubMed/NCBI
|
